

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/050057 A2

- (51) International Patent Classification⁷: A61K 9/00 [CA/CA]; 11820 boulevard O'Brien, Montréal, Québec H4J 1Y8 (CA).
- (21) International Application Number: PCT/CA2003/001899 (74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).
- (22) International Filing Date: 4 December 2003 (04.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/430,690 4 December 2002 (04.12.2002) US
- (71) Applicants (for all designated States except US): TECHNOLOGIES BIOLACTIS INC. [CA/CA]; 345 rue des Saguenéens, 2e étage, Bureau 290, Chicoutimi, Québec G7H 6K9 (CA). INRS (INSTITUT NATIONAL DE RECHERCHE SCIENTIFIQUE) [CA/CA]; Bureau 640, C.P. 7500, 2600 Boulevard Laurier, Sainte-Foy, Québec G1V 4C7 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BEAUDET, Nicolas [CA/CA]; 851 Chemin Brookbury, Bury, Québec J0B 1J0 (CA). DUPONT, Claude [CA/CA]; 7, rue de Fermont, Blainville, Québec J7B 1L6 (CA). LEMIEUX, Pierre [CA/CA]; 97, Des Chênes, Ste-Thérèse, Québec J7E 4Z2 (CA). SIMARD, Eric [CA/CA]; 585 de Largentière, App. 1, Laval, Québec H7N 4A1 (CA). GOYETTE, Philippe
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/050057 A2

(54) Title: AN EXOPOLYSACCHARIDES DELIVERY SYSTEM FOR ACTIVE MOLECULES

(57) Abstract: The present invention relates to a delivery system for delivery of an active molecule to a patient, the delivery system comprising a population of exopolysaccharide micelles, each micelle defining a core for containing the active molecule.

RECEIVED AVAILABLE COPY

AN EXOPOLYSACCHARIDES DELIVERY SYSTEM FOR ACTIVE MOLECULES

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

This invention relates to exopolysaccharide delivery system of active molecules into a patient and/or increase the activity of the active molecules.

(b) Description of Prior Art

10 Encapsulation of bioactive compounds in natural or synthetic matrices has been extensively studied over the past decades. Advantages of encapsulation are numerous. Firstly, it provides protection from the inactivation or degradation of the bioactive compound. Secondly, it controls the kinetics of compound release, allowing the optimization of the
15 blood concentration profile. Thirdly, it can also improve therapeutic indices of bioactive compounds like that described with micellar systems. This optimization diminishes the deleterious effects of bioactive compounds with short half lives. In addition, it permits a reduction in toxicity or synergize with the formulated drugs leading to a better treatment for the patient.

20 Many systems have been described to improve formulation of bioactive compounds. Among them are found colloidal drug delivery systems that are promising such as liposomes, microspheres, nanospheres and block copolymer micelles that increase the therapeutic index and improve the selectivity of various potent drugs (Gregoriadis G.,
25 (1995) TIBS, 13:527-537; Muller R.H., (1991) Colloidal Carriers for Controlled Drug Delivery and Targeting: Modification, Characterization and In vivo Distribution, CRC Press Inc., Florida; Kabanov A.V., Alakhov V. Y. (1997) " Micelles of Amphiphilic Block Copolymers as Vehicles for Drug Delivery" In Amphiphilic Block Copolymers: Self-Assembly and
30 Applications edited by Alexamdris P., Lindman B., Elsevier, Netherlands; Kwon G. et al. (1997) J. Controlled Release, 48:195-201; La S.B. et al. (1996) Journal of Pharmaceutical Sciences, 85:85-90; Kataoka K: et al. (1992) J. Control. Release, 24:119-132). These vehicles optimize the therapeutic efficacy of drugs by preventing their rapid elimination from the

body, reducing their systemic toxicity, delaying their degradation and optimizing their metabolism (Muller R. H. (1991) *supra*; Kabanov A. V., Alakhov V. Y. (1997) *supra*). In addition, they also provide for effective delivery of drugs to specific target sites (Muller R. H., (1991) *supra*) and aid
5 in overcoming both transport limitations and defense mechanisms associated with the multi-drug resistance phenotype.

Various approaches have been developed to provide continuous delivery of various biologically active agents, and, although these have overcome some of the problems of delivering the agents, numerous
10 problems remain such as the linearity of release, bioavailability, absorption, biocompatibility of the materials used and loading capacity.

It would be highly desirable to be provided with a natural biopolymers forming micelles, being easily and inexpensively produced, that are enabling the delivery of an active molecule to a patient.

15 SUMMARY OF THE INVENTION

One aim of the invention is to use exopolysaccharides (EPS) micelles as a drug delivery system.

Another aim of the present invention is to describe a method of production of exopolysaccharides having micellar properties.

20 The active molecule may be lipophilic, hydrophilic, hydrophobic.

The micellar system of the present invention is also suitable to the cosmetic industry such as in the delivery of active agents in creams, toiletries, deodorants, skin and sunscreen preparation. The micellar system of the present invention is also useful in perfumes, by stabilizing
25 the unstable components thereof and by controlling the release kinetics of the fragrance upon application.

In accordance with the present invention there is provided a delivery system for delivery of an active molecule to a patient, the delivery system comprising a population of exopolysaccharide micelles, each
30 micelle defining a core for containing the active molecule.

In a preferred embodiment of the present invention, the exopolysaccharide is produced by lactic acid bacteria, more preferably the

bacteria is selected from the group consisting of *Lactobacillus* strain R2C2, *Lactobacillus* strain Inix, *Lactobacillus* strain Es1, *Lactobacillus* strain K2. Alternatively, the exopolysaccharide can be produced by a yeast like, but not limited to *Candida kefyr* or *Candida norvegensis*.

- 5 In accordance with a preferred embodiment of the present invention, the active molecule is selected from the group consisting of DNA, RNA, protein, peptide, peptidomimetic, virus, bacteria, nutraceutical product and pharmaceutical agent. Preferably, the pharmaceutical agent is selected from the group consisting of analgesic, anesthetic, antibiotic,
10 anticancer, anti-inflammatory, and antiviral.

- The anticancer agent is preferably selected from the group consisting of alkylating agents, alkyl sulfonates, aziridines, ethylenimines, methylamelamines, acetogenins, camptothecin, bryostatin, callystatin, CC-1065, cryptophycins, dolastatin, duocarmycin, eleutherobin, pancratistatin,
15 sarcodictyin, spongistatin, nitrogen mustards, nitrosureas, antibiotics, anti-metabolites, folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate, purine analogs, pyrimidine analogs, androgens, anti-adrenals, folic acid replenisher, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestabucil, bisantrene,
20 edatraxate, defofamine, demecolcine, diaziquone, elformithine, elliptinium acetate, epothilone, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansinoids, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, PSK.RTM., razoxane, rhizoxin, sizofiran,
25 spirogermanium, tenuazonic acid, triaziquone, 2, 2',2"-trichlorotriethylamine, trichothecenes, urethan, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside, thiotepa, taxanes, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, methotrexate, platinum, vinblastine, platinum, etoposide,
30 ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, navelbin, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylomithine, retinoic acid, capecitabine, bisphosphonates and anti-hormonal agents that act to regulate or inhibiting hormone action in hormonal dependent
35 cancers.

The anti-hormonal agent is preferably an anti-estrogens or an anti-androgens selected from the group consisting of flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, and pharmaceutically acceptable salts, acids or derivatives thereof.

- 5 The alkylating agents are preferably selected from the group consisting of thiotepa and cyclophosphamide (CYTOXAN™).

The alkyl sulfonates are preferably selected from the group consisting of busulfan, improsulfan and piposulfan.

- 10 The aziridines are preferably selected from the group consisting of benzodopa, carboquone, meturedopa, and uredopa.

The methylamelamines are preferably selected from the group consisting of altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine.

- 15 The acetogenins are preferably selected from the group consisting of bullatacin and bullatacinone.

The camptothecin is preferably the synthetic analogue topotecan.

The CC-1065 is preferably selected from the group consisting of adozelesin, carzelesin and bizelesin synthetic analogues thereof.

- 20 The cryptophycins are preferably selected from the group consisting of cryptophycin 1 and cryptophycin 8.

The duocarmycin is preferably selected from the group consisting of KW-2189 and CBI-TMI.

- 25 The nitrogen mustards are preferably selected from the group consisting of chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide and uracil mustard.

- 30 The nitrosureas are preferably selected from the group consisting of carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine.

The anti-metabolites are preferably selected from methotrexate and 5-fluorouracil (5-FU).

The purine analogs are preferably selected from the group consisting of fludarabine, 6-mercaptopurine, thiamiprine and thioguanine.

5 The pyrimidine analogs are preferably selected from the group consisting of ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine and floxuridine.

 The androgens are preferably selected from the group consisting of calusterone, dromostanolone propionate, epitiostanol, mepitiothane,
10 testolactone.

The anti-adrenals are preferably selected from the group consisting of aminoglutethimide, mitotane and trilostane.

 The antibiotics are preferably selected from the group consisting of enediyne antibiotics, aclacinomysins, actinomycin, anthramycin,
15 azaserine, bleomycins, cactinomycin, carabycin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin,
20 mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, poffiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin.

 The enediyne antibiotics are preferably selected from the group consisting of calicheamicin more preferably calicheamicin γ 11 and
25 calicheamicin θ 11, dynemicin more preferably dynemicin A, esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores.

 In accordance with a preferred embodiment of the present invention, the micelles have a diameter varying from about 50 nanometers
30 to about 700 nanometers.

 In accordance with the present invention, there is provided a pharmaceutical composition comprising the delivery system of the present

invention in association with a pharmaceutically acceptable carrier and method of use thereof.

5 In accordance with the present invention, there is provided an immunomodulator composition comprising an immunomodulating amount of the delivery system of the present invention in association with a pharmaceutically acceptable carrier and method of use thereof.

10 In accordance with the present invention, there is provided a method for producing the delivery system of the present invention, comprising the step of incubating exopolysaccharide in a suitable medium for a time sufficient to form micelle.

Administration of the delivery vehicle of the present invention can be performed by a route selected from the group consisting out local, parenteral, peritoneal, mucosal, dermal, epidermal, subcutaneous, transdermal, intramuscular, nasal, oral, topical, vaginal, rectal, intra-ocular, 15 intravenous, intra-arterial and by inhalation.

For the purpose of the present invention the following terms are defined below.

20 The term "active molecule" is intended to mean, without limitations, nonpolar, lipophilic drugs, vitamins, polar molecules, immunosuppressants, immunoactive agents, neutraceuticals, peptidomimetics mimicking growth factors and their antagonists and immunomodulator agents

All references herein are hereby incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

25 Fig. 1 illustrates scans of pyrene dissolved in PBS, P85 and EPS;

Fig. 2 is an electronic microscopy image of pure EPS micelles; and

30 Fig. 3 is an electronic microscopy image of EPS micelles having 1% critical micellar concentration.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a delivery system comprising exopolysaccharide micelles for delivering an active molecule to a patient.

5 Exopolysaccharides (EPS) produced by lactic acid bacteria (LAB) are known to act as viscosifying agents in fermented foods (Yang, Z. (2000) Antimicrobial and extracellular polysaccharides produced by lactic acid bacteria: Structures and properties, PhD thesis, University of Helsinki, Helsinki, 61 pp.) and as cytokine inducers *in vitro* (Chabot, S. et al, (2001) 10 Lait, 81:683-697). The rheological and immunomodulator properties of EPS are based on their monomeric composition and their assembling, conferring to those molecules a neutral to charged tri-dimensional structure that can actively interact with its environment. It was observed during the use of pyrene, an insoluble molecular probe in water, a modification of its 15 fluorescent profile in the presence of EPS in comparison to the pluronic P85 (a tri-block copolymer known to form micelles in solution) profile in the same conditions. The temperature of formation is from room temperature to 37°C. The micelles formed rapidly and were left undisturbed for a period of 16 to 24 hours to allow equilibration before fluorescence reading. The 20 estimated critical micellar concentration (0.007% (w/v)) and the presence of a significant excimer peak show that EPS is a potential high loading drug carrier, since the excimer state is attributable to molecular stacking of pyrene in an enclosed environment. An electronic microscopy analysis has been processed on EPS samples, showing semi-spherical structures 25 resembling monolayer liposomes. EPS represents an easy-to-produce, at a reasonable cost, bio-degradable polymer that is naturally derived from lactic acid bacteria (LAB) which are food-grade microorganisms with the GRAS status (Generally Recognized As Safe) (see Figs. 2 and 3). It is understood herein that any bacteria capable of producing a polymer is 30 enclosed in the definition of a bacteria suitable to produce the EPS of the present invention. It is also understood that one having ordinary skills in the art would know what bacteria are suitable for pharmaceutical applications as described in the present application.

The micellar delivery system of the present invention is able to incorporate much higher concentrations of pyrene as compared to P85 (see Example 6) that will later be released slowly over time. This prevents at least some of the damaging effects that high doses induce..

5 The results obtained by the use of the exopolysaccharide micellar system of the present invention reveal that EPS is an effective delivery vehicle for the delivery of various active molecules including lipophilic drugs. The small size and high *in vitro* stability of the micelles render them useful for a wide variety of biomedical applications. Their
10 loading capacity for the very hydrophobic pyrene compound shows that it allows incorporation of several different compounds with a high degree of hydrophobicity.

 The degree of non-covalent incorporation of physical entrapment of a hydrophobic drug into a micelle is determined by the partition
15 coefficient of the drug between the micellar core and the surrounding aqueous medium. The affinity of the exopolysaccharide micelles for lipophilic compounds was assayed by the determination of the partitioning coefficient (solubilization) for the hydrophobic model compound, pyrene, between the exopolysaccharide micelles and water. This method has been
20 previously used to determine the partitioning coefficient of pyrene between several polymeric formulations forming micelles and water and the critical micellar concentration (CMC). This fluorescence method is based on pyrene's sensitivity to the hydrophobicity of its microenvironment. This is reflected in changes in the ratio of the I_3/I_1 bands of its emission spectrum
25 (see Fig. 1). The method requires the measurement of the I_3/I_1 ratio for pyrene in micelle solutions of various solvent mixtures. The CMC is calculated by plotting either the I_3/I_1 (aqueous) peak fluorescence values over the concentrations of polymers or exopolysaccharide. The ratio is at first a measurement of the polarity of the solvent. This plot has a S-shape and the inflection point corresponds to the CMC. Furthermore, by plotting I_3
30 (test solution) on I_3 (aqueous) for a range of concentration gives an idea of the capacity to solubilize the pyrene (partitioning coefficient). Finally, I_4 or I_e which corresponds to the peak of excimer (pile up of ground state and excited pyrene molecules) represents an accumulation of pyrene in an
35 hydrophobic microdomain. By plotting I_4 or I_e (test solution) on I_4 or I_e

(aqueous or control) for a range of concentration gives an indication about the magnitude of pyrene accumulation in hydrophobic pocket like micelles or micellar like structure. Also, the ratio I_4 or I_6 (test solution) on I_3 (test solution) represents the degree of friction in the hydrophobic domains. A high ratio is a sign of high viscosity.

The *in vitro* toxicity of the exopolysaccharide micelles was tested by incubating the micelles with a wide range of cell lines for 4-hour, 8-hour, 72-hour and 96-hour periods. The XTT™ or Alamar Blue™ assays were used to quantify the survival rates in the presence of the exopolysaccharide micelles. The capability of the exopolysaccharide to deliver an active molecule was first tested *in vitro* using 5-Fluorouracil (5-Fu) as a model active molecule. The 4-hour and 8-hour exposure time were removed from the analysis due to the absence of reaction, 5-Fu being a low action drug and EPS showing no toxicities at those times. The 5-Fu/exopolysaccharide formulation was incubated with either B16F10 (murine skin melanoma), Caco-2 (human colon adenocarcinoma) or IEC-6 (rat epithelial small intestine) cells over 72-hour to 96-hour. Vital dyes (XTT or Alamar Blue) were added to supernatants for a period of 4 hours. Absorbance values were collected and plotted to evaluate the survival rate of the cells to the treatment. The results from XTT or Alamar Blue survival assays (Example 6) show a synergy between the EPS and the drug. It is also shown that combined use of 5-Fu and EPS has a higher cytotoxicity than the use of 5-Fu or EPS alone.

Beside the enhancement of *in vitro* toxicity of a drug which shows a synergy, EPS were used to formulate various molecules like fluorescein, rhodamine, 5-Fu, paclitaxel to demonstrate that EPS change the pharmacokinetic of those molecules (see Example 8) and cause an improvement of absorption, reduction of elimination, increase C_{max} , and higher AUCs which leads to better therapeutic efficacy of 5-FU and paclitaxel (see Examples 9 and 10). A better efficacy translate into better overall survival or delay of death.

The exopolysaccharides are easy to use since there is no need for micelle preparation. The exopolysaccharides were dissolved in PBS pH 7.2 and incubated overnight at room temperature, which led to the

spontaneous formation of the EPS micellar structure. Micellization process with exopolysaccharide is different than the conventional preparation of micelles (like P85) which is achieved by the addition of water in a dropwise fashion to a solution to form a micelle solution and the micelle solution did
5 not need to be stirred overnight and then dialyzed against milli-Q™ distilled water using dialysis tubing with a change of water every hour for the first four hours and then every three hours for the next twelve hours like it is usually done.

The present invention describes the formation of micelles of
10 different size composed of exopolysaccharide, preferably ranging from 50 to 700nm. The exopolysaccharide can be isolated from, but not limited to, *Lactobacillus* strain R2C2, *Lactobacillus* strain Inix, *Lactobacillus* strain Es1, *Lactobacillus* strain K2.

The exopolysaccharide not only can form micelles but can act as
15 a biological response modifying agent on cells. As shown in Example 8, exopolysaccharide can activate genes in keratinocytes which shows that exopolysaccharides can be used not only as a drug delivery system but may have a synergistic effect with various drugs.

EXAMPLE 1

20 Extraction of EPS

EPS are extracted from biomass of a consortium of bacteria and yeast strains that include without limitation to the following ones: *Lactobacillus* strain R2C2, *Lactobacillus* strain Inix, *Lactobacillus* strain Es1, *Lactobacillus* strain K2, *Candida kefyr*, *Candida norvegensis*. EPS
25 can also be produced from the purified bacterial strain mentioned above.

EXAMPLE 2

Crude preparation and production of EPS

Biomass (either consortium or purified bacterial stain) is added to hot water (0.5 to 5% (w/v)). The temperature of the solution is brought to
30 95°C and agitation is applied for a dissolution time of 3 hours. Dissolution of biomass is visually monitored and when no further dissolution occurs the incubation is pursued for an extra hour. A primary filtration is performed to remove aggregates and debris and the filtrate centrifuged. For large

volumes (10L and over) a primary tangential filtration (0.45 μ M) is performed to remove aggregates and debris. Filtrate is then concentrated by tangential filtration (3 kDaltons) to a minimal volume. Retentate is centrifuged at 7500g for 15 minutes to remove the precipitate. An equal
5 volume of ice cold ethanol 100% (-70) is added to the supernatant to precipitate the exopolysaccharides for 16h. After centrifugation 7500g, 4°C for 15 minutes, the supernatant is discarded and the pellet resuspended in a minimal volume of water. Solution is centrifuged at 7500g for 15 minutes. The supernatant containing EPS is freeze-dried to yield the pure
10 EPS.

EXAMPLE 3

Purified preparation of EPS

Biomass (either consortium or purified bacterial strain) is added to hot water (0.5 to 5% (w/v)). The temperature of the solution is brought
15 to 95°C and agitation is applied for a dissolution time of 3 hours. Dissolution of biomass is visually monitored and when no further dissolution occurs the incubation is pursued for an extra hour. A primary filtration is performed to remove aggregates and debris. For large volumes (10L and over) a primary tangential filtration (0.45 μ M) is performed to
20 remove aggregates and debris. Filtrate is concentrated by tangential filtration (3 kDaltons) to a minimal volume. Retentate is centrifuged at 7500g for 15 minutes to remove the precipitate. An equal volume of ice cold ethanol 100% (-70) is added to the supernatant to precipitate the exopolysaccharides for 16h. After centrifugation 7500g, 4°C for 15
25 minutes, the supernatant is discarded and the pellet resuspended in a minimal volume of water. Solution is centrifuged at 7500g for 15 minutes. The supernatant containing EPS is freeze-dried to yield the pure EPS.

EXAMPLE 4

Fractionation of EPS

30 Pure EPS are solubilized in water and fractionated by serial passages on membrane of different molecular weight cutoff. As example, when the membranes used are of 100 000, 50 000, 10 000 and 3 000 kDa, it yield fraction of EPS with the following range of molecular weight: EPS >

100 000 kDa, 50 000 kDa <EPS>100 000 kDa, 10 000 kDa <EPS>50 000 kDa, 3 000 kDa<EPS>10 000 kDa, EPS<3 000 kDa.

EXAMPLE 5

Measurement of critical micelle concentration (CMC) of EPS using Pyrene

5 A 1% solution of EPS (w/v) in PBS was prepared. The solution was vortexed for 2 minutes until EPS is well resuspended. Multiple dilutions were performed to obtain 2 ml of 0.1%, 0.01%, 0.001% EPS solution. In parallel, a series of borosilicate tubes were prepared to which
10 20 μ l of a pyrene solution (50 μ M solubilized in acetone (Sigma Aldrich cat. No. 18-551-5)) were added. The solutions were allowed to dry prior to the addition of the various EPS solutions. Once dried, 2 ml of the EPS solutions were transferred into the borosilicate tubes to be tested. This is called a redissolution test or solubilization or partitioning between water
15 and test conditions. The control tube (containing PBS only) was placed in the cell holder set at 37°C of an Varian Eclipse™ fluorometer set at Excitation: 340nm, Emission: 350-600nm. Samples were incubated over time and read to obtain the partitioning coefficient and CMC measurement. CMC is calculated according to the standard protocols as
20 described previously. The data of Table 1 show the ratio of fluorescence intensity of peak I₃ over intensity of peak I₂ from PBS solution as a function of the concentration of EPS and P85. This data show that the EPS can solubilize the insoluble probe (pyrene) as much if not more than P85 from the range 0,001% to 0,1%. At higher concentration (1%), P85 seems to
25 keep forming conventional micelles while the EPS start to decline which is explained by a shift in the spectrum profile. This shift is indicative of excimers formation.

Table 1

Ratio of fluorescence intensity of peak I_3 over intensity of peak I_3 from PBS solution in function of the concentration of EPS and P85

| Concentration | P85 | EPS lot 2 |
|---------------|-------|-----------|
| 0,001% | 1,107 | 1,125 |
| 0,01% | 1,168 | 1,690 |
| 0,1% | 2,564 | 3,989 |
| 1% | 8,813 | 3,476 |

- 5 The data of Table 2 show the ratio of fluorescence intensity of peak I_e over intensity of peak I_e from PBS solution in function of the concentration of EPS and P85. This data show that EPS triggers a higher formation of excimer than P85.

Table 2

- 10 **Ratio of fluorescence intensity of peak I_e over intensity of peak I_e from PBS solution in function of the concentration of EPS and P85**

| Concentration | P85 | EPS lot 2 |
|---------------|--------|-----------|
| 0,001% | 0,9619 | 2,241 |
| 0,01% | 1,233 | 19,51 |
| 0,1% | 2,443 | 60,31 |
| 1% | 4,829 | 11,97 |

- 15 The data of Table 3 show the ratio of fluorescence intensity of peak I_e over intensity of peak I_m as a function of the concentration of EPS and P85. This data show that the EPS are more viscous than P85.

Table 3

Ratio of fluorescence intensity of peak I_e over intensity of peak I_m as a function of the concentration of EPS and P85

| Concentration | P85 | EPS lot 2 |
|---------------|---------|-----------|
| 0,001% | 0,06239 | 0,1430 |
| 0,01% | 0,07580 | 0,8293 |
| 0,1% | 0,06841 | 1,086 |
| 1% | 0,03935 | 0,2472 |

- 5 The data of Table 4 show the ratio of fluorescence intensity of peak I_3 over intensity of peak I_1 in function of the concentration of EPS and P85. This data show that both P85 and EPS are apolar media.

Table 4

10 **Ratio of fluorescence intensity of peak I_3 over intensity of peak I_1 in function of the concentration of EPS and P85**

| Concentration | P85 | EPS lot 2 |
|---------------|--------|-----------|
| 0,001% | 0,9271 | 0,9119 |
| 0,01% | 0,9226 | 1,031 |
| 0,1% | 0,9538 | 1,257 |
| 1% | 0,9892 | 1,328 |

EXAMPLE 6

Formulation of 5FU with EPS and studies on B16, IEC-6 and Caco-2 cells

- 15 Caco-2, IEC-6 and melanocytes B16 cells were cultured in DMEM supplemented with 10% FBS. The cells were seeded at 2×10^3 cells per well in a 96-well plate and left to rest 24 hours before EPS exposure at various concentrations and also with or without 5FU (0,001 $\mu\text{g/ml}$ to 10 $\mu\text{g/ml}$). The cells were grown in a CO_2 incubator for 4 extra

days. Cell survival was assessed with XTT™ according to manufacturer's recommendation. The data obtained show a synergistic effect between 5FU and the EPS while EPS show no or only modest toxicity. Furthermore, on differentiated Caco-2 cells, EPS from consortium show no toxicity neither alone nor in formulation unlike on proliferative Caco-2 cells where the synergy of EPS is evident. The data are as follows:

Table 5

Survival of IEC-6 rat normal small intestine epithelial cells in presence of different concentrations of 5-fluorouracil and exopolysaccharides

| µg/ml | 5-Fu alone | EPS 1% + 5-Fu | EPS 0.1% + 5-Fu | EPA 0.01% + 5-FU |
|-------|-------------|---------------|-----------------|------------------|
| 0 | 100.1 ± 5.2 | 64.2 ± 14.8 | 86.0 ± 4.3 | 97.0 ± 11.1 |
| 5 | 16.9 ± 6.4 | 0.0 ± 2.1 | 0.0 ± 4.8 | 5.4 ± 1.5 |
| 50 | 28.0 ± 4.6 | 7.1 ± 3.5 | 9.3 ± 6.3 | 8.1 ± 5.1 |
| 250 | 35.4 ± 8.2 | 0.4 ± 3.1 | 18.2 ± 6.5 | 37.2 ± 11.7 |
| 500 | 33.4 ± 3.5 | 0.0 ± 5.3 | 22.1 ± 4.1 | 8.3 ± 4.6 |

Table 5 illustrates the results of three days exposure treatments run in quadruplicate and cell survival was revealed by absorbance using the vital dye Alamar Blue™ (Medicorp, Mtl). [NB073]. Percentages of EPS are expressed in (w/v).

Table 6

Survival of IEC-6 rat normal small intestine epithelial cells in presence of different concentrations of 5-Fluorouracil and exopolysaccharides

| µg/ml | 5-Fu alone | EPS 1% + 5-Fu | EPS 0.1% + 5-Fu | EPA 0.01% + 5-FU |
|-------|-------------|---------------|-----------------|------------------|
| 0 | 100.0 ± 1.9 | 0.0 ± 6.7 | 91.8 ± 2.3 | 91.3 ± 2.1 |
| 1 | 78.0 ± 3.0 | 0.0 ± 4.3 | 76.7 ± 0.3 | 84.9 ± 1.5 |
| 10 | 75.4 ± 2.9 | 0.0 ± 4.7 | 76.4 ± 0.6 | 83.2 ± 3.1 |
| 50 | 81.8 ± 2.1 | 0.0 ± 4.4 | 71.7 ± 1.1 | 80.6 ± 2.2 |
| 100 | 80.2 ± 0.9 | 0.0 ± 1.2 | 67.0 ± 1.8 | 66.8 ± 2.7 |

Table 6 illustrates the results of three days exposure treatments run in quadruplicate and cell survival was revealed by absorbance using the vital dye Alamar Blue™ (Medicorp, Mtl). [NB073]. Percentages of EPS are expressed in (w/v).

5

Table 7

Survival of Caco-2 human colon adenocarcinoma cells in proliferation in presence of different concentrations of 5-Fluorouracil and exopolysaccharides

| µg/ml | 5-Fu alone | EPS 0.1% + 5-Fu (consortium) | EPS 0.1% + 5-Fu (pure strain) |
|-------|-------------|---------------------------------|----------------------------------|
| 0 | 100.0 ± 1.2 | 98.0 ± 1.1 | 101.8 ± 2.3 |
| 1 | 74.1 ± 1.9 | 60.5 ± 3.4 | 119.7 ± 4.7 |
| 10 | 78.6 ± 2.4 | 34.2 ± 0.8 | 36.3 ± 0.5 |
| 50 | 80.3 ± 1.8 | 46.4 ± 1.4 | 52.2 ± 1.3 |
| 100 | 52.6 ± 4.8 | 47.4 ± 1.2 | 41.0 ± 1.1 |

10 Table 7 illustrates the results of four days exposure treatments were run in octuplicate and cell survival was revealed by absorbance using the vital dye XTT™ (Sigma, St-Louis) [NB050]. Percentages of EPS are expressed in (w/v).

Table 8

15 **Survival of Caco-2 human colon adenocarcinoma cells differentiated in presence of different concentrations of 5-Fluorouracil and exopolysaccharides**

| µg/ml | 5-Fu alone | EPS 0.1% + 5-Fu (consortium) | EPS 0.1% + 5-Fu (pure strain) |
|-------|-------------|---------------------------------|----------------------------------|
| 0 | 100.0 ± 4.0 | 97.8 ± 1.9 | 105.7 ± 4.2 |
| 1 | 105.7 ± 4.2 | 100.9 ± 5.1 | 69.2 ± 0.3 |
| 10 | 85.6 ± 8.8 | 108.7 ± 4.4 | 75.4 ± 5.2 |
| 50 | 99.6 ± 6.8 | 98.3 ± 6.0 | 71.9 ± 2.8 |
| 100 | 78.1 ± 0.7 | 88.2 ± 3.6 | 77.2 ± 1.6 |

Table 8 illustrates the results of four days exposure treatments were run is octuplicate and cell survival was revealed by absorbance using the vital dye XTT™ (Sigma, St-Louis) [NB050]. Percentages of EPS are expressed in (w/v).

5

Table 9

Survival of B16F10 murine skin melanoma cells in presence of different concentrations of 5-Fluorouracil and expolysaccharides

| µg/ml | 5-Fu alone | EPS 0.1% + 5-Fu (consortium) | EPS 0.1% + 5-Fu (pure strain) |
|-------|-------------|---------------------------------|----------------------------------|
| 0 | 100.0 ± 4.1 | 95.8 ± 9.6 | 56.4 ± 4.5 |
| 1 | 62.6 ± 6.6 | 20.5 ± 1.4 | 21.2 ± 1.4 |
| 10 | 65.4 ± 10.4 | 35.4 ± 10.7 | 26.4 ± 3.4 |
| 50 | 54.9 ± 8.9 | 18.7 ± 2.7 | 28.2 ± 4.9 |
| 100 | 38.8 ± 8.5 | 20.9 ± 6.5 | 26.8 ± 2.6 |

Table 9 illustrates the results of four days exposure treatments were run is octuplicate and cell survival was revealed by absorbance using the vital dye XTT™ (Sigma, St-Louis) [NB050]. Percentages of EPS are expressed in (w/v).

10

EXAMPLE 7**Biological effects of EPS on keratinocytes**

HEKa (human epithelial keratinocytes, adult, Cascade Biologics), grown in Medium 154 supplemented with human keratinocyte growth supplement (HKGS), were exposed to exopolysaccharide (10 μ g/ml) and the RNA extracted using Rneasy purification columns (Qiagen) as per manufacturers specifications. The RNA samples from control and treated cells was labeled with Cy3 and Cy5 respectively, and applied to human 1.7K microarray (Microarray Centre, University Health Network, Toronto) for competitive hybridization. Exopolysaccharides regulate the expression of a variety of genes that may be advantageous for cosmeceutical purposes but also shows that they are not inert and modulate genes that indicate the type of drugs that be formulated with EPS.

Table 10**Genes regulated by Exopolysaccharides**

| Down regulated genes | Up regulated genes |
|-----------------------------|----------------------------------|
| Tumor necrosis factor (TNF) | TGF-beta induced (TGFBi) |
| Cyclooxygenase 2 (COX) | Transglutaminase 2 (Tgase 2) |
| | Transgelin (TAGLN2) |
| | Thrombospondin 1 (THBS1) |
| | Keratin 7 (KRT7) |
| | Ferritin light polypeptide (FTL) |

EXAMPLE 8**Change of pharmacokinetic of markers with EPS**

Fluorescein (FL) pharmacokinetic on unfasten Wistar female rats of 200g and 8 weeks of age. Fluorescein concentration is 1 mg/kg. Exopolysaccharides (EPS) are diluted in water at 1% and 5% (w/v). Fluorescein is added to the latter solutions and vortexed. Formulations are fed to the animals with a canula. 200 μ l blood samples are collected through the jugular vein every 30 minutes for 2.5 hours. A final bleeding is

- made at 3.5h. Plasma are collected immediately after centrifugation (10 min @ 1300g). Plasma are frozen on dry ice until further analysis: 50 μ l of plasma are diluted in 550 μ l of saline 0.7% (w/v) and analyzed with a Varian Eclipse Spectrofluorometer (Excitation: 495nm Emission: 515nm).
- 5 Concentrations were determined on a fluorescein standard curve (FL diluted in saline 0.7% and 50 μ l of normal serum as in the sample analysis).

Table 11
Fluorescein concentrations over time

| Time (h) | FL-Water | Std Err | FL-EPS 1% | Std Err | FL-EPS 5% | Std Err |
|----------|----------|---------|-----------|---------|-----------|---------|
| 0.0 | 37.10 | 3.55 | 54.79 | 15.40 | 36.77 | 3.38 |
| 0.5 | 218.30 | 49.40 | 298.26 | 24.61 | 360.46 | 62.08 |
| 1.0 | 145.95 | 19.92 | 319.20 | 166.54 | 151.50 | 62.78 |
| 1.5 | 75.25 | 19.83 | 140.76 | 68.07 | 136.04 | 38.69 |
| 2.0 | 74.48 | 17.46 | 73.09 | 21.14 | 95.66 | 25.78 |
| 2.5 | 71.74 | 14.57 | 48.31 | 10.39 | 92.44 | 22.45 |
| 3.5 | 54.63 | 10.28 | 70.60 | 31.08 | 88.47 | 26.78 |

- EPS used at 1% and 5% show a better absorption than non formulated fluorescein. Higher Cmax were obtained for both concentration around 1h after the gastric intubation. Overall, EPS 5% show a better absorption of the drug up to 3.5h. The result of a better absorption is superior AUC for both concentration of EPS this translating to a better drug exposure and thus better treatments (see Example 10).

15 **EXAMPLE 9**

Formulation of B16 tumors in muscle following i.m. injection of B16 cells treated with a formulation of paclitaxel

- Fifteen mice in group P1 (100x stock = 100 mM or 85,3 mg/ml, prepared from powdered stock in DMSO) and fourteen mice in group P2 (10X stock = 10mM in 1% EPS (in PBS), or 8.5 mg/ml, prepared from 100 μ l P1 in 900 μ l 1% EPS (in PBSP)). Cells (50000 cells per 50 μ l
- 20

injections) for a concentration of 10^6 cells per ml. The remaining of the test was performed as follows:

- 5 ▪ Cells from 1XT₇₅ (80% confluence) are trypsinized with 2ml trypsin, diluted in 12 ml media, spun down, rinsed once in 5ml PBS, and resuspended in 2ml PBS. Cells are then counted and concentration adjusted to 10^6 cells per ml.
- 10 ▪ P1 treatment: Add 20 μ l P1 stock and 180 μ l PBS of cell suspension (10^6 cells) and incubate at room temperature 3 hrs. Final Paclitaxel = 1mM, DMSO = 1%.
- 15 ▪ P2 treatment: Add 200 μ l P2 stock to 1.8ml of cell suspension (10^6 cells) and incubate at room temperature 3 hrs. Final Paclitaxel = 0.1mM, DMSO = 1%, EPS = 0.1%.
- 15 ▪ 1ml of cells from P1 and P2 treatment groups were replated following a rinse in PBS. No growth was observed from either group after 2 weeks in culture.

Table 12
Tumor-free mice (%)

| Formulation | P1 | P2 |
|-------------------------------|----------|----------|
| Growth in tissue culture | negative | negative |
| Intramuscular tumor formation | 12/15 | 1/14 |

20 Cells treated with Paclitaxel do not have the capacity to recover from this treatment in tissue culture, however, in an environment rich in nutrients and growth factors, such as *in vivo* within the muscle, the cells can recover from the drug and form intramuscular tumors. However, as shown herein, the presence of EPS potentiates the effect of Paclitaxel in this model.

EXAMPLE 10**Treatment with a 5FU/EPS formulation of mice grafted with B16 cells injected i.p.**

Tumor cells were trypsinized and washed 3 times with PBS.

5 Cells (1x10E6) were injected i.p. to Balb/c mice to induce a cancer in the peritoneal cavity. After 4 days of implantation, treatments of 5FU alone (100mg/kg) or EPS alone (0.1% w/v) or a combination of both were given to the mice. Survival was observed for 44 days from day 0 of injection. An additive effect was observed between EPS and 5FU from day 29 leading to

10 a better survival than the group treated with 5FU alone. EPS alone show efficacy until day 29 compared with other treatments but protects the animals better overall. This highlighting again that EPS are not inert and may contribute to the therapeutic index.

Table 13

15 **Tumor-free mice over time (%)**

| Days | Saline (Placebo) | 5-FU | EPS 0.1% (w/v) | EPS 0.1% (w/v) + 5-FU |
|-------------|-----------------------------|-------------|-----------------------|------------------------------|
| 0 | 100 | 100 | 100 | 100 |
| 15 | 12.5 | 62.5 | 37.5 | 62.5 |
| 29 | 12.5 | 12.5 | 37.5 | 37.5 |
| 44 | 12.5 | 12.5 | 37.5 | 25 |

EXAMPLE 11**Modification of the pharmacokinetic of Rhodamine formulated with EPS**

20 The pharmacokinetic of Rhodamine 123 (R123) was performed on unfasten Wistar female rats of 200g and 8 weeks of age. Rhodamine concentration is 5 mg/kg. Exopolysaccharides (EPS) were diluted in water at 1% and 3% (w/v). Rhodamine is added to the latter solutions and vortexed. Formulations are fed to the animals with a canula and 200µl

25 blood samples are collected through the jugular vein every hour for 4 hours (plus 1 sample at 0.5h). Plasma are collected immediately after

- centrifugation (10 min @ 13000g). Plasma are frozen on dry ice until further analysis: 50 μ l of plasma are diluted in 550 μ l of saline 0.7% (w/v) and analyzed with a Varian Eclipse™ Spectrofluorometer (Excitation: 505nm Emission: 540nm). Concentrations were determined on a
- 5 Rhodamine 123 standard curve (R123 diluted in saline 0.7% and 50 μ l of normal serum as in the sample analysis). The data are as follows:

Table 14
Rhodamine 123's concentration over time

| Time (h) | R123 – Water (ng/ml) | R123 – EPS 1% (ng/ml) | R123 – EPS 3% (ng/ml) |
|----------|-------------------------|--------------------------|--------------------------|
| 0.0 | 2.2 \pm 2.2 | 0.2 \pm 0.1 | 1.3 \pm 0.7 |
| 0.5 | 20.4 \pm 2.2 | 10.1 \pm 2.2 | 21.7 \pm 4.2 |
| 1.0 | 20.9 \pm 2.6 | 11.6 \pm 3.0 | 24.3 \pm 3.5 |
| 2.0 | 15.4 \pm 2.0 | 9.1 \pm 2.9 | 20.2 \pm 4.8 |
| 3.0 | 10.9 \pm 1.4 | 6.0 \pm 1.2 | 20.3 \pm 4.6 |
| 4.0 | 11.2 \pm 1.8 | 3.0 \pm 0.7 | 15.7 \pm 3.6 |

- 10 Rhodamine formulated with EPS used at 3% show approximately the same absorption as in water except that the AUC (area under the curve) is increased. Absorption, distribution and elimination seem to be closely linked between those two groups showing no influence of the EPS in the blood circulation. EPS 1%, on their side, show a peculiar
- 15 profile. The absorption is slower and lower. EPS 1% might retain the R123, preventing it from penetrating in the blood stream or EPS 1% could stay with R123 and block its fluorescence.

- While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of
- 20 further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential

features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A delivery system for delivery of an active molecule to a patient, said delivery system comprising a population of exopolysaccharide micelles, each said micelle defining a core for containing said active molecule.
2. The delivery system of claim 1, wherein said exopolysaccharide is produced by lactic acid bacteria.
3. The delivery system of claim 2, wherein said bacteria is selected from the group consisting of *Lactobacillus* strain R2C2, *Lactobacillus* strain Inix, *Lactobacillus* strain Es1, *Lactobacillus* strain K2, *Candida kefyr* and *Candida norvegensis*.
4. The delivery system of claim 1, wherein said active molecule is selected from the group consisting of DNA, RNA, protein, peptide, peptidomimetic, virus, bacteria, nutraceutical product and pharmaceutical agent.
5. The delivery system of claim 4, wherein said pharmaceutical agent is selected from the group consisting of analgesic, anesthetic, antibiotic, anticancer, anti-inflammatory, and antiviral.
6. The delivery system of claim 5, wherein said anticancer agent is selected from the group consisting of alkylating agents, alkyl sulfonates, aziridines, ethylenimines, methylamelamines, acetogenins, camptothecin, bryostatin, calystatin, CC-1065, cryptophycins, dolastatin, duocarmycin, eleutherobin, pancratistatin, sarcodictyin, spongistatin, nitrogen mustards, nitrosureas, antibiotics, anti-metabolites, folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate, purine analogs, pyrimidine analogs, androgens, anti-adrenals, folic acid replenisher, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elformithine, elliptinium acetate, epothilone, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansinoids, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, PSK.RTM., razoxane,

rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2',2"-trichlorotriethylamine, trichothecenes, urethan, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside, thiotepa, taxanes, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, methotrexate, platinum, vinblastine, platinum, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, navelbin, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, anti-hormonal agents that act to regulate or inhibiting hormone action in hormonal dependent cancers.

7. The delivery system of claim 6, wherein said anti-hormonal agent is an anti-estrogens or an anti-androgens selected from the group consisting of flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, and pharmaceutically acceptable salts, acids or derivatives thereof.

8. The delivery system of claim 6, wherein said alkylating agents is selected from the group consisting of thiotepa and cyclophosphamide (CYTOXAN™).

9. The delivery system of claim 6, wherein said alkyl sulfonates is selected from the group consisting of busulfan, improsulfan and piposulfan.

10. The delivery system of claim 6, wherein said aziridines is selected from the group consisting of benzodopa, carboquone, meturedopa, and uredopa.

11. The delivery system of claim 6, wherein said methylamelamines is selected from the group consisting of altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine.

12. The delivery system of claim 6, wherein said acetogenins is selected from the group consisting of bullatacin and bullatacinone.

13. The delivery system of claim 6, wherein said camptothecin is the synthetic analogue topotecan.

14. The delivery system of claim 6, wherein said CC-1065 is selected from the group consisting of adozelesin, carzelesin and bizelesin synthetic analogues thereof.
15. The delivery system of claim 6, wherein said cryptophycins is selected from the group consisting of cryptophycin 1 and cryptophycin 8.
16. The delivery system of claim 6, wherein said duocarmycin is selected from the group consisting of KW-2189 and CBI-TMI.
17. The delivery system of claim 6, wherein said nitrogen mustards is selected from the group consisting of chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide and uracil mustard.
18. The delivery system of claim 6, wherein said nitrosureas is selected from the group consisting of carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine.
19. The delivery system of claim 6, wherein said anti-metabolites is selected from methotrexate and 5-fluorouracil (5-FU).
20. The delivery system of claim 6, wherein said purine analogs is selected from the group consisting of fludarabine, 6-mercaptopurine, thiamiprine and thioguanine.
21. The delivery system of claim 6, wherein said pyrimidine analogs is selected from the group consisting of ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine and floxuridine.
22. The delivery system of claim 6, wherein said androgens is selected from the group consisting of calusterone, dromostanolone propionate, epitiostanol, mepitiothane, testolactone.
23. The delivery system of claim 6, wherein said anti-adrenals is selected from the group consisting of aminoglutethimide, mitotane and trilostane.
24. The delivery system of claim 5, wherein said antibiotics is selected from the group consisting of enediyne antibiotics, aclacinomysins,

actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabycin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, poffiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin.

25. The delivery system of claim 24, wherein said enediyne antibiotics is selected from the group consisting of calicheamicin, dynemicin, esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores.

26. The delivery system of claim 25, wherein said calicheamicin is selected from the group consisting of calicheamicin γ_1^I and calicheamicin θ_{11} .

27. The delivery system of claim 25, wherein said dynemicin is dynemicin A.

28. The delivery system of claim 1, wherein said micelles are having a diameter varying from about 50 nanometers to about 700 nanometers.

29. A pharmaceutical composition comprising the delivery system of any one of claims 1 to 28 in association with a pharmaceutically acceptable carrier.

30. An immunomodulator composition comprising an immunomodulating amount of the delivery system of any one of claims 1 to 28 in association with a pharmaceutically acceptable carrier.

31. A method for delivering an active molecule to a patient comprising the step of administering the composition of claim 29 to said patient.

32. The method of claim 31, wherein said administering can be from a route selected from the group consisting out local, parenteral, peritoneal, mucosal, dermal, epidermal, subcutaneous, transdermal, intramuscular, nasal, oral, topical, vaginal, rectal, intra-ocular, intravenous, intra-arterial and by inhalation.

33. A method for inducing immunomodulation in a patient comprising the step of administering the composition of claim 30 to said patient.

34. The method of claim 33, wherein said administering can be from a route selected from the group consisting out local, parenteral, peritoneal, mucosal, dermal, epidermal, subcutaneous, transdermal, intramuscular, nasal, oral, topical, vaginal, rectal, intra-ocular, intravenous, intra-arterial and by inhalation.

35. Use of the composition of claim 29 for delivering an active molecule to a patient.


36. The use as claimed in claim 35, wherein said delivering can be from a route selected from the group consisting out local, parenteral, peritoneal, mucosal, dermal, epidermal, subcutaneous, transdermal, intramuscular, nasal, oral, topical, vaginal, rectal, intra-ocular, intravenous, intra-arterial and by inhalation.

37. Use of the composition of claim 30 for inducing immunomodulation in a patient.

38. The use as claimed in claim 37, wherein said delivering can be from a route selected from the group consisting out local, parenteral, peritoneal, mucosal, dermal, epidermal, subcutaneous, transdermal, intramuscular, nasal, oral, topical, vaginal, rectal, intra-ocular, intravenous, intra-arterial and by inhalation.

39. A method for producing the delivery system of claim 1, comprising the step of incubating exopolysaccharide in a suitable medium for a time sufficient to form micelle.

1/2



2/2



FIG. 2




FIG. 3

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.